c-MYB- and PGC1α-dependent metabolic switch induced by MYBBP1A loss in renal cancer

Blanca Felipe-Abrio1,2, Eva M. Verdugo-Sivianes1,2 and Amancio Carnero1,2

1 Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío (HUVR), Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Spain
2 CIBER de Cáncer, Instituto de Salud Carlos III, Madrid, Spain

Keywords
- c-MYB; metabolism; MYBBP1A; PGC1α; renal cancer

Correspondence
A. Carnero, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Seville 41013, Spain
E-mail: acarnero-ibis@us.es

(Received 11 March 2019, revised 24 April 2019, accepted 7 May 2019, available online 11 June 2019)

doi:10.1002/1878-0261.12499

The tumor microenvironment may alter the original tumorigenic potential of tumor cells. Under harsh environmental conditions, genetic alterations conferring selective advantages may initiate the growth of tumor subclones, providing new opportunities for these tumors to grow. We performed a genetic loss-of-function screen to identify genetic alterations able to promote tumor cell growth in the absence of glucose. We identified that downregulation of MYBBP1A increases tumorigenic properties under nonpermissive conditions. MYBBP1A downregulation simultaneously activates PGC1α, directly by alleviating direct repression and indirectly by increasing PGC1α mRNA levels through c-MYB, leading to a metabolic switch from glycolysis to OXPHOS and increased tumorigenesis in low-glucose microenvironments. We have also identified reduced MYBBP1A expression in human renal tumor samples, which show high expression levels of genes involved in oxidative metabolism. In summary, our data support the role of MYBBP1A as a tumor suppressor by regulating c-MYB and PGC1α. Therefore, loss of MYBBP1A increases adaptability spanning of tumors through metabolic switch.

1. Introduction

The host microenvironment in which tumor cells are located may alter the original tumorigenic potential of these cells. Specific microenvironmental conditions may select for the most robust clone, allowing it to hierarchically evolve, which generates a large tumor mass. Conversely, the same cell located in a nonpermissive environment may not contribute to tumor growth. Impaired vascularization during early and later stages of tumor growth causes an altered microenvironment that lacks oxygen and nutrients, which greatly impairs the development of tumors (Carnero and Lleonart, 2016). In these cases, hypoxia has emerged as an essential factor for tumor physiology by promoting tumor initiation, progression, and resistance to therapy. Hypoxia has been related to changes in cellular metabolism by providing an alternative source of nutrients at a very high cost of glucose consumption (Kroemer and Pouyssegur, 2008). Even in the presence of oxygen, cancer cells switch from generating ATP by the highly energy-efficient process of oxidative phosphorylation to the much less efficient process of glycolysis. Undoubtedly, we now know that this metabolic switch, called the Warburg effect, is an important feature of cancer cells.

Abbreviations
- 2DG, 2-deoxy-D-glucose; ccRCC, clear cell renal cell carcinoma; chRCC, chromophobe renal cell carcinoma; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MYB, avian myeloblastosis viral oncogene homolog; MYBBP1A, MYB-binding protein 1α; NRD, negative regulatory domain; PPARGC1A/PGC1α, peroxisome proliferator-activated receptor-gamma coactivator 1/PPAR-gamma coactivator 1-alpha; pRCC, papillary renal cell carcinoma; ROS, reactive oxygen species; shRNA, short hairpin ribonucleic acid; TCGA, The Cancer Genome Atlas; VHL, von Hippel–Lindau.
(Warburg, 1956). Aerobic glycolysis facilitates cellular transformation by producing high levels of glycolytic intermediates that cancer cells need for the biosynthesis of lipids, amino acids, and nucleic acids (Cairns et al., 2011). However, before neovascularization replenishes a tumor with new blood vessels, the tumor is subjected to very low glucose conditions. Under these critical environmental conditions, genetic alterations that provide selective advantages may initiate the growth of tumor subclones, providing new opportunities for these tumors. Heterogeneous tumors made up of different clones are able to adapt to different environmental conditions, providing the basis for therapy resistance.

The peroxisome proliferator-activated receptor γ coactivator (PGC1α) is a known regulator of mitochondrial oxidative metabolism. PGC1α was first discovered as a coactivator of the adipogenic nuclear receptor PPARγ (Puigserver et al., 1998). By binding to several transcription factors and nuclear receptors, PGC1α induces the activation of genes involved in the tricarboxylic acid cycle (TCA cycle), oxidative phosphorylation, fatty acid beta-oxidation, mitochondrial biogenesis, and mitochondrial reactive oxygen species (ROS) detoxification (Scarpulla, 2011; Ventura-Clapier et al., 2008). Furthermore, PGC1α suppresses glycolysis in melanoma tumors (Lim et al., 2014), and it has been proposed as a potential suppressor of glycolysis through NRF-1 control of von Hippel-Lindau (VHL; Scarpulla, 2011). Therefore, PGC1α is a transcription factor coactivator that influences the majority of cellular metabolic pathways and several crucial aspects of energy metabolism. The expression of PGC1α is rapidly induced in situations that demand mitochondrial production of heat or ATP, such as cold exposure, short-term exercise, and fasting (Kelly and Scarpulla, 2004). Abnormal expression of PGC1α is associated with several chronic diseases, and in recent years, it has been shown to be a critical controller of cancer development. The characteristic traits of PGC1α in maintaining metabolic homeostasis promote cancer cell survival and tumor metastasis in harsh microenvironments (Tan et al., 2016).

The 160-kDa MYB-binding protein 1A (MYBBP1A, p160) is a repressor of PGC1α and can be a key regulator of metabolic processes. MYBBP1A interacts with the negative regulatory domain (NRD) of PGC1α and reduces its ability to stimulate mitochondrial respiration and electron transport system-related gene expression. This negative regulation is removed when PGC1α is phosphorylated by p38 MAPK (Fan et al., 2004). The ubiquitously expressed MYBBP1A was originally found to interact with the c-MYB oncoprotein. MYBBP1A binds to the leucine zipper motif in the NRD of c-MYB (Tavner et al., 1998). MYBBP1A also binds to several other transcription factors, such as p53, enhancing its acetylation and accumulation (Kumazawa et al., 2015; Ono et al., 2014).

MYBBP1A is located on chromosome 17p13.3, which loses heterozygosity at high frequency (up to 50–80%) in different malignancies (Keough et al., 1999). Besides its role as a nucleolar transcriptional regulator, MYBBP1A is essential in mice prior to blastocyst formation, is involved at premitotic level, and may display tumor suppressor activity (Mori et al., 2012). In addition, MYBBP1A is regulated by the VHL tumor suppressor (Lai et al., 2011), which regulates MYBBP1A degradation in an iron- and proteasome-dependent manner. Therefore, MYBBP1A could also be involved in the metabolic plasticity of cancer cells. However, there is not completely understood the molecular mechanism through which MYBBP1A would regulate the tumor metabolism.

In this work, we performed a genetic loss-of-function screen to identify genetic alterations that promote growth in the absence of glucose. We identified that downregulation of MYBBP1A switches glycolytic metabolism to oxidative phosphorylation (OXPHOS) by activating PGC1α directly and indirectly through c-MYB activation. Interestingly, only renal cancer cell lines that express high levels of c-MYB and do not express vHL can take advantage of the cellular metabolism switch and increase tumorigenesis. We also analyzed public transcriptome databases and found that reduced MYBBP1A expression is correlated with high expression of genes involved in oxidative metabolism in a percentage of cases. Our data strongly support the role of MYBBP1A as a tumor suppressor via regulation of c-MYB and PGC1α.

2. Materials and methods

2.1. Cell culture

All human renal tumor cell lines were obtained from Cell Line Service (CLS) (Eppelheim, Germany), which performed the authentication test. ACHN and A498 were maintained in DMEM (AQmedia; Sigma, St. Louis, MO, USA). 786-0 and CaKi-1 were maintained in RPMI 1640 (AQmedia; Sigma). For the surrogate assays, RPMI 1640 without glucose (Gibco, Paisley, UK) and DMEM without glucose (Gibco) were used. For metabolic assays, RPMI (Bio-West, Nuaille, France) and DMEM (Corning, Corning, NY, USA) without l-glutamine, sodium pyruvate, and glucose were used. GlutaMAX (Gibco) or glucose was added depending on the experimental requirements. All
media were supplemented with 10% FBS (Gibco), penicillin, streptomycin, and fungizone (Sigma). Normoxia is considered at 21%. Hypoxia is defined usually at 3% oxygen. When 1% or 5% oxygen is used for hypoxia, this is specified in the experiment.

2.2. Genetic loss-of-function screen

Library generation was performed as described previously (Leal et al., 2008). Transduction of the library and recovery of the proviruses were performed as previously described by Carnero and coworkers (Leal et al., 2008). For selection, NIH3T3 cells were cultured in media without glucose.

2.3. RNA array hybridization

Cancer profiling array membranes (BD Biosciences, Franklin Lanes, NJ, USA) were prehybridized with ExpressHyb hybridization solution for 4 h at 65 °C. The appropriate probe was then labeled by PCR with 50 °C of redive dCTP32 (Amersham, Buckinghamshire, UK). The labeled probe was then purified from free hot nucleotides with a sepharose G-50 column Nick (Amersham). The purified probe was then denatured for 3 min at 100 °C and added to the hybridization solution. The hybridization was performed overnight at 65 °C. Then, the membrane was washed at 65 °C two times with 29 SSPE, 0.1% SDS; once with 19 SSPE, 0.1% SDS; and once more with 0.19 SSPE, 0.1% SDS. The membrane was then exposed to a Bio-max MS film (Kodak, Rochester, NY, USA).

2.4. Transfections and plasmids

Subconfluent cells were transfected with TransIT-X2 reagent (Mirus, Madison, WI, USA) according to the manufacturer’s instructions. At 48 h, cells were seeded in 10-cm plates with media containing a selection drug (0.5–1 µg·mL⁻¹ puromycin, 50 µg·mL⁻¹ hygromycin B, and 400 µg·mL⁻¹ G418). Cells were transfected with the following plasmids: pGene Clip-hygromycin negative control (GGAATCTATTCGATGCATAC) (QUIAGEN, Hilden, Germany), referred through the text as V; pGeneClip shMYBBP1A (TCCCTGTCACGCC-TACTTTCT) (QIAGEN #3336312 KH08420H), referred through the text as sh; pRetrosuper-puro, referred through the text as V2; pRetrosuper shMYBBP1A (GAGAGAGAGTTCAAGAGACT CTTCAGACTGGTTTCTTTCTGGA), referred through the text as sh2; pRetrosuper scramble negative control (OriGene #TR30012, Rockville, MD, USA), pRetrosuper shPGC1α (TCTGGGTACACAAAGGCAAT AACTCCACCAA) (OriGene #TR310260C), pBABE-puro, pBABE-puro-YFP, pcDNA3-neomycin, and pcDNA3-2xFlag-human-c-MYB (kindly provided by Shengao Jin).

2.5. Competition assay

Equal number (50% vs 50%) of V-YFP+ cells (control), doubled transfected with pGene Clip-hygromycin negative control and pBABE-puro-YFP vectors, and shMYBBP1A cells, doubled transfected with pGeneClip shMYBBP1A and pBABE-puro vectors, were seeded in the same dish at complete, low-glucose, and glutamine-only media. Percentage of cells was analyzed by FACS the day after seeding. Then, cells were cultured during 15–30 days and the final percentage of cells was counted on an analyzer cytometer (Cedex, France) FACS BD Fortessa.

2.6. Growth curve assay and growth in soft agar

We followed a protocol previously described by Guijarro et al. (2007) in different media conditions.

2.7. Xenografted tumors

Tumorigenicity was assayed by the subcutaneous injection of 5 × 10⁶ cells of 786-O and 10⁶ of ACHN, A498, and CaKi-1 cell lines into the right flanks of 4-week-old female athymic nude mice. Animals were examined weekly. After 100 or 180 days, depending on cell lines, mice were sacrificed, tumors were extracted and conserved under −80 °C until RNA extraction. All animal experiments were performed according to the experimental protocol approved by the IBIS and HUVR Institutional Animal Care and Use Committee (0309-N-15).

2.8. Sensitivity to rotenone

In a 96-well plate, 5 × 10³ cells per well were seeded in media with 100 mg·L⁻¹ glucose without glutamine or media with glutamine but without glucose. Cells were cultured under normoxic and hypoxic (5%) conditions. After 14–18 h, cells were treated with increasing concentrations of rotenone (0–300 µM) (R8875; Sigma). After 24 h, cell viability was measured with the MTS assay (G3581; Promega, Fitchburg, WI, USA) according to the manufacturer’s instructions.

2.9. Sensitivity to 2-deoxy-D-glucose

In a 6-well plate, 10³ cells per well were seeded in full media. Cells were treated with 2-deoxy-D-glucose
2.10. Mitochondrial ROS measurement

In a 6-well plate, 1.5 x 10^5 cells per well were seeded in full media, low-glucose media, and glutamine-only media. After 16–18 h, fresh media were added 30 min before beginning the MitoSox protocol. After the media were removed, 1 mL of MitoSox Red (Invitrogen #M36008, Eugene, OR, USA) at 5 µM final concentration was added in each well, and cells were incubated in the dark. Labeled cells were suspended in PBS containing 2% FBS and 5 mM EDTA and analyzed on a FACS Canto II cytometer (Franklin Lakes, NJ, USA).

2.11. Q-RT–PCR

Total RNA from cell lines and xenografted tumors was purified using the ReliaPrep™ RNA Tissue Miniprep System (Promega) according to the manufacturer's instructions. Reverse transcription was performed with 1 µg of mRNA using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies, Carlsbad, CA, USA), according to the manufacturer’s recommendations. The PCR mixture (10 µL) contained 2 µL of the reverse transcriptase reaction product diluted 1 : 3, 2.5 µL of water, 5 µL of GoTaqR Probe qPCR Master Mix (Promega), and 0.5 µL of the appropriate TaqMan Assay (20x) (Applied Biosystems, Buckinghamshire, UK). We used the following probes: β-actin (Hs0160665_g1), MYBBP1A (Hs00959671_m1), MYB (Hs00920556_m1), PGC1α (Hs01016719_m1), SGLT1 (Hs01573790_m1), GLUT4 (Hs00168966_m1), HK2 (Hs00606086_m1), PFKM (Hs00175997_m1), GAPDH (Hs03929097_g1), PGK1 (Hs00943178_g1), PGAM1 (Hs01652468_g1), PKM (Hs00761782_g1), and LDHA (Hs01378790_g1).

2.12. Protein isolation and western blot analysis

Western blots were performed as previously described elsewhere. Membranes were incubated with the following primary antibodies: anti-MYBBP1A (Proteintech #14524-AP, Rosemont, IL, USA), anti-PGC1α (Abcam #ab54481, Cambridge, UK), anti-SGLT1 (Abcam #ab14685), anti-p38 MAPK (Cell Signaling #9212, Danvers, MA, USA), and anti-phospho-p38 MAPK (T180/Y182) (Cell Signaling #9215). α-Tubulin (Sigma #T9026) was used as a loading control. Horse-radish peroxidase-labeled rabbit anti-mouse (Abcam #ab 97046) and goat anti-rabbit (Abcam #ab 97051) secondary antibodies were used. The proteins were detected using an ECL detection system (Amersham Biosciences) and Bio-Rad ChemiDoc XRST (Berkeley, CA, USA).

2.13. Statistical analyses

Statistical analyses of experiments were performed using GRAPHPAD PRISM (La Jolla, CA, USA) (6.01 for Windows). Control samples and MYBBP1A shRNA samples were compared using the unpaired Student’s t-test or Student’s t-test with Welch’s correction, as appropriate. Experiments were performed for a minimum of three times independently and always performed in triplicate samples.

2.14. Analysis of cancer patient databases

We used the R2 Genomics analysis and visualization platforms (http://hgserver1.amc.nl). We used six databases, grouped into three sets: EXPO (including several renal tumor subtypes), TCGA (composed of three tumor simple databases: clear cell renal cell carcinoma database (ccRCC), papillary renal cell carcinoma database (pRCC), and chromophobe renal cell carcinoma (chRCC), and Dykema-Kort (composed of two mixed databases that contain normal and tumor samples). To determine the genes whose expression correlates with MYBBP1A expression, we analyzed the following KEGG pathways: ‘glycolysis and gluconeogenesis' and ‘TCA cycle’. We also added the list of transcription factors that are targets of MYB gene defined in the GeneCards database (http://www.genecards.org) to the R2 platform and analyzed the correlation of the expression of these genes with MYBBP1A expression. We selected genes that correlate with MYBBP1A expression with a P-value < 0.05. KEGG classification of the overlapped genes was performed with the Enrich platform (http://amp.pharm.mssm.edu/Enrichr/). Finally, heat maps of genes from ‘transcription factors target of MYB gene’ were generated using cityblock distances. Heat maps of TCA cycle genes were generated by Euclidean distance.

3. Results

3.1. MYBBP1A loss in human tumors

To identify signals with the ability to overcome environmental stress, providing new directions for tumor
evolution, we performed a genetic loss-of-function screen (Leal et al., 2008). NIH3T3 cells were seeded and infected with a saturated library of antisense fragments. Then, cells were grown in the absence of glucose (Fig. S1A). We identified one antisense fragment that reduced MYBBP1A protein expression by 50% and allowed the cells to grow under these restrictive conditions (Fig. S1B).

However, if the downregulation of MYBBP1A is an important trait required for the evolution of these cells, it must be maintained throughout tumor growth; therefore, we should be able to identify it in human tumors. To this end, we first checked MYBBP1A expression in several arrays of paired normal/tumor tissue samples from the same patients. We identified pancreas, liver, and renal tumors as those in which the signal was significantly decreased by at least 50% with respect to normal tissue (Fig. S2). Furthermore, pVHL activation of PGC1 in xenografted tumors from ACHN and CaKi-1 cell lines (Fig. 1E).

As the downregulation of MYBBP1A induces the activation of PGC1α only in cells with high levels of c-MYB, we also explored whether c-MYB may mediate PGC1α activation by MYBBP1A reduction. Thus, we overexpressed c-MYB in CaKi-1 cells and measured the expression of PGC1α, GLUT4, and CXCR4 (a target gene of c-MYB controlled by c-MYB transactivation activity) (Quintana et al., 2011) (Fig. 2A). We observed increases in PGC1α and GLUT4 mRNA levels upon c-MYB overexpression (Fig. 2A). A similar increase in PGC1α was observed in c-MYB-positive cells after MYBBP1A was downregulated (Fig. 2B). In addition, we previously reported that A498 MYBBP1A-downregulated cells metastasized in some host mice before the primary tumors reached large sizes while control cells did not, the MYBBP1A levels being lower in metastasis than in primary tumors from xenografted mice (Felipe-Abrio et al., 2019). We wondered whether PGC1α expression pattern would be different in primary tumors versus metastasis, so we measured PGC1α mRNA levels and we found an increase in PGC1α in metastasis compare with primary tumors from A498-downregulated cells (Fig. S4).

Alternatively, we downregulated PGC1α expression in 786-O cell line using shRNA to explore whether PGC1α affects c-MYB expression levels. We observed that PGC1α downregulation has no effect on c-MYB mRNA levels (Fig. 2C).

Taken together, our data show that MYBBP1A downregulation deregulates the expression of glycolytic genes. To confirm this, we measured the mRNA levels of several glycolytic genes and we found that downregulation of MYBBP1A represses HK2, PFKM, PGAM1, and PGK1, which may decrease glycolysis in 786-O and A498 cells under low glucose concentration (Fig. 1D). Reduction of HK2 transcription was reproduced with a second shRNA against MYBBP1A (Fig. S3). On the other hand, the expression of these genes was not reduced in c-MYB-negative cell lines when MYBBP1A was downregulated (Fig. 1D). This result was also obtained in vivo, where we observed reduced expression of HK2 and LDHA in xenografted tumors from 786-O and A498 cells with downregulated MYBBP1A compared to tumors from control cells. Again, this reduction was not observed in xenografted tumors from ACHN and CaKi-1 cell lines (Fig. 1E).

3.2. MYBBP1A downregulation activates PGC1α

To explore the effect of MYBBP1A downregulation on the four renal carcinoma cell lines selected (Table S1), we silenced MYBBP1A with a shRNA and achieved approximately 40–50% reduction of the protein (Fig. 1A). Previous literature data suggest a direct relationship between MYBBP1A and PGC1α since MYBBP1A may bind and repress PGC1α (Fan et al., 2004). This binding is disrupted by p38 phosphorylation of PGC1α (Fan et al., 2004). To study this relationship in our cellular model, we measured the levels of PGC1α, phosphorylated p38, and SGLT1 (a target gene of PGC1α) (Corpe et al., 2001; Yu et al., 2017). We observed an increase in PGC1α levels and an upwards shift of the PGC1α band, probably due to post-translational phosphorylation that occurs only in A498 and 786-O cells. We also observed an increase in phosphorylated p38 and SGLT1 levels in these cells (Fig. 1B).

To confirm the activation of PGC1α due to MYBBP1A downregulation, we measured the transcriptional expression of two PGC1α target genes: SGLT1 and GLUT4 (Corpe et al., 2001; Michael et al., 2001; Oriente et al., 2008; Yu et al., 2017). We observed an increase in the mRNA levels of both transporters when we reduced the expression of MYBBP1A in cells that express c-MYB, but this increase was not observed in the c-MYB-negative cell lines ACHN and CaKi-1 (Fig. 1C).

It has been suggested that PGC1α represses glycolysis (Lim et al., 2014), so we wondered whether MYBBP1A downregulation derepresses the expression of glycolytic genes. To confirm this, we measured the mRNA levels of several glycolytic genes and we found that downregulation of MYBBP1A represses HK2, PFKM, PGAM1, and PGK1, which may decrease glycolysis in 786-O and A498 cells under low glucose concentration (Fig. 1D). Reduction of HK2 transcription was reproduced with a second shRNA against MYBBP1A (Fig. S3). On the other hand, the expression of these genes was not reduced in c-MYB-negative cell lines when MYBBP1A was downregulated (Fig. 1D). This result was also obtained in vivo, where we observed reduced expression of HK2 and LDHA in xenografted tumors from 786-O and A498 cells with downregulated MYBBP1A compared to tumors from control cells. Again, this reduction was not observed in xenografted tumors from ACHN and CaKi-1 cell lines (Fig. 1E).

As the downregulation of MYBBP1A induces the activation of PGC1α only in cells with high levels of c-MYB, we also explored whether c-MYB may mediate PGC1α activation by MYBBP1A reduction. Thus, we overexpressed c-MYB in CaKi-1 cells and measured the expression of PGC1α, GLUT4, and CXCR4 (a target gene of c-MYB controlled by c-MYB transactivation activity) (Quintana et al., 2011) (Fig. 2A). We observed increases in PGC1α and GLUT4 mRNA levels upon c-MYB overexpression (Fig. 2A). A similar increase in PGC1α was observed in c-MYB-positive cells after MYBBP1A was downregulated (Fig. 2B). In addition, we previously reported that A498 MYBBP1A-downregulated cells metastasized in some host mice before the primary tumors reached large sizes while control cells did not, the MYBBP1A levels being lower in metastasis than in primary tumors from xenografted mice (Felipe-Abrio et al., 2019). We wondered whether PGC1α expression pattern would be different in primary tumors versus metastasis, so we measured PGC1α mRNA levels and we found an increase in PGC1α in metastasis compare with primary tumors from A498-downregulated cells (Fig. S4).
3.3. Metabolic plasticity in MYBBP1A-downregulated cells

Metabolic plasticity relies on the ability of cells to rewire the existing metabolic pathways depending on cellular needs and nutrient availability. One of the most important metabolic adaptations in absence of glucose is to use glutamine for energy production and anabolic reactions, which enhances OXPHOS metabolism. During glutaminolysis, glutamine is converted into α-ketoglutarate, which enters directly into the Krebs cycle. To measure the metabolic plasticity of cells with reduced expression of MYBBP1A, we cultured the 786-O cell line in different conditions of nutrient limitation. Tumor cells expressing the control vector do not grow in medium containing only glutamine (Fig. 3A); however, cells with low levels of MYBBP1A grow fast (Fig. 3A), indicating a switch to

Fig. 1. Downregulation of MYBBP1A induces direct activation of PGC1α. (A) Downregulation of MYBBP1A by the expression of a specific shRNA. Cell lines were transfected with MYBBP1A shRNA (sh) or a scramble vector (V). After selection, cells were grown to 80% confluence, and proteins were extracted. The figure shows the western blot results of MYBBP1A expression in all cell lines and the quantification of MYBBP1A expression in cells expressing MYBBP1A shRNA (sh) related to the scramble vector (V). (B) PGC1α, SGLT1, p38, and p-p38 (T180/Y182) levels at high- (4500 mg/L) and low-glucose (100 mg/L) media were measured by WB. (C) A498, 786-O, ACHN, and CaKi-1 cells expressing the scramble vector (V) or MYBBP1A shRNA (sh) were cultured in low-glucose (100 mg/L) media. SGLT1 and GLUT4 mRNA levels were measured by Q-RT-PCR. Graphs show mRNA levels of cells with reduced levels of MYBBP1A (sh) related to control cells (V). (D) A498, 786-O, ACHN, and CaKi-1 cells expressing the scramble vector (V) or MYBBP1A shRNA (sh) were cultured in low-glucose (100 mg/L) media. HK2, PFKM, GAPDH, PGK1, PGAM1, and PKM mRNA levels were measured by Q-RT-PCR. Graphs show mRNA levels of cells with reduced levels of MYBBP1A (sh) related to control cells (V). (E) Quantification of HK2 and LDHA levels from xenografted tumors (N = 4) by Q-RT-PCR. Graphs show mRNA levels of cells with reduced levels of MYBBP1A (sh) related to control cells (V). (C–E) Graphs show the mean ± SD of three independent experiments performed in triplicate. (C–E) Statistical test: unpaired Student’s t-test with Welch’s correction, *P < 0.05; **P < 0.01; ***P < 0.001.
OXPHOS metabolism. Similar effects can be observed when the cells were grown under very low glucose concentrations (Fig. 3B). The effect is even more obvious when the cells were grown under glutamine and low glucose concentrations (Fig. 3C). In this media, control cells showed initial growth as consequence of the low glucose. However, the growth of cells with low MYBBP1A is twofold to fourfold faster (Fig. 3C).

Finally, during hypoxia, the advantage of having oxygen disappears for cells using OXPHOS, and both cell strains grow equally regardless of the ATP source (Fig. 3D).

The complex I of the mitochondrial electron transport chain is used to produce ATP in OXPHOS metabolism (Lorendeau et al., 2016). Rotenone inhibits this complex and is very poisonous to cells, but interestingly, it is identically toxic for both control cells and cells with low MYBBP1A levels that are growing in the presence (Fig. 3E) or absence (Fig. 3F) of oxygen in media only containing glutamine. However, for cells growing under low glucose conditions, which allow some plasticity and reorientation to cells growing in the presence of oxygen, rotenone is significantly more toxic in cells with reduced levels of MYBBP1A, while control cells are more resistant to this poison (Fig. 3G). However, under hypoxic conditions, this difference disappears because the lack of oxygen prevents metabolism reorientation (Fig. 3H). Similar data were obtained using a second shRNA against MYBBP1A (Fig. S5).

Alternatively, we tested the sensitivity of A498, 786-O, and ACHN cells to 2DG, a well-known inhibitor of glycolysis. We seeded the cells at low density and cultured them in media with or without 2-DG. A498,
and 786-O MYBBP1A-downregulated cells formed more colonies than control cells in both control and 2DG treatment conditions (Fig. 3I, Fig. S6), pointing to an increased resistance to 2DG treatment. However, MYBBP1A downregulation in the ACHN cell line reduced the number of colonies in both conditions (Fig. 3I, Fig. S6). The increased resistance to 2DG of c-MYB-positive cells also suggests a switch to oxidative metabolism.

To explore whether MYBBP1A downregulation increases metabolic plasticity in different molecular contexts, we performed surrogated tumorigenic assays with A498, ACHN, and CaKi-1 cell lines in low-glucose media. We found that A498 cells with reduced levels of MYBBP1A grew faster than cells expressing only the empty vector (Fig. S7A). However, ACHN and CaKi-1 grew at the same rate in both the control cells and the cells with MYBBP1A downregulation.
Similar data were obtained in a soft agar assay; A498 cell lines with reduced levels of MYBBP1A formed more colonies than cells expressing scramble vector (Fig. S7B). However, ACHN and CaKi-1 with reduced MYBBP1A formed the same number of colonies or an even lower number than the control cells (Fig. S7B).

We also confirmed the reorientation toward OXPHOS by measuring mitochondrial ROS, as mitochondrial superoxide is generated as a by-product of oxidative phosphorylation. To this end, we cultured control and MYBBP1A-downregulated 786-O and ACHN cells in either high- or low-glucose media or glutamine-only media, and we measured mitochondrial ROS by flow cytometry. We observed an increase in mitochondrial ROS in 786-O cells with reduced MYBBP1A when the cells were cultured in glutamine-only media, but there was no difference in the ACHN cell line (Fig. 3J).

Finally, since our aim was to discover genetic events that give competitive advantage in harsh microenvironments, we performed competition assays. We cocultured control cells (labeled with YFP, V-YFP+) and equal number cells with reduced MYBBP1A (with empty vector, shMYBBP1A) in the same dish and with different media conditions and let the mix population evolve. At day 1, equal number of V-YFP+ (control) and shMYBBP1A (50% vs 50%) were seeded in the same dish (Table 1). We observed that the percentage of each subpopulation barely changed after coculture the three cell lines tested (786-O, ACHN, and A498) at high glucose condition. However, at low-glucose or in glutamine-only media, the percentage of control V-YFP+ cells at the end of the experiment was greatly reduced in 786-O and A498 cells, indicating that the cells with low MYBBP1A were more competitive and grew better overcoming the control population in these restrictive conditions. However, in ACHN cells, we observed an increase in the control subpopulation, indicating that in this cell line the reduction of MYBBP1A did not provide a selective advantage in these restrictive media (Table 1).

Taken together, our data indicate that cells with downregulated MYBBP1A have a higher metabolic plasticity regarding glucose limitation, being able to rewire their metabolism to OXPHOS. Interestingly, the effect of MYBBP1A is observed in cells with c-MYB, which regulates PGC1α.

### 3.4. MYBBP1A expression in renal cancer and its role in tumor progression

To examine the role of MYBBP1A in human tumor progression, in relation to an increase in c-MYB and PGC1α, we used public transcriptome databases. First, we analyzed the expression of MYBBP1A, VHL, PGC1α, and MYB genes, functionally related in our cellular model. We focused on the samples with highest and lowest expression levels of MYBBP1A (approximately 6% of the samples) and observed that samples with low levels of MYBBP1A show low levels of VHL and high levels of PGC1α. In contrast, samples with high expression levels of MYBBP1A show high levels of VHL and low levels of PGC1α (Fig. 4A).

To determine whether there is a relationship between MYBBP1A, c-MYB, and PGC1α in human renal tumors, we studied c-MYB target genes that had a negative correlation with MYBBP1A and a positive correlation with PGC1α expression with a P-value < 0.05 in at least two of the three databases analyzed. We obtained a list of 54 genes involved in various pathways (Fig. 4B). When we classify these genes by KEGG pathway analysis, we observed that most of the genes belong to metabolic pathways (Fig. 4C). Moreover, the heat map generated using the EXPO database with these 54 genes showed that approximately 8% of samples have low MYBBP1A expression.

### Table 1. Coculture experiments in different media.

| Coculture | Glucose 4500 mg·L⁻¹ | Glucose 100 mg·L⁻¹ | Glutamine |
|-----------|----------------|----------------|----------|
|           | % V-YFP+ cells | % V-YFP+ cells | % V-YFP+ cells |
| 786-O V-YFP vs 786-O shMYBBP1A | Day 1 | Day 15 | Day 1 | Day 15 | Day 1 | Day 15 |
| | 50 | 52.8 | 50 | 17.5 | 50 | 21.2 |
| A498 V-YFP vs A498 shMYBBP1A | Day 1 | Day 30 | Day 1 | Day 30 | Day 1 | Day 30 |
| | 50 | 59.7 | 50 | 9.4 | 50 | 10 |
| ACHN V-YFP vs ACHN shMYBBP1A | Day 1 | Day 15 | Day 1 | Day 15 | Day 1 | Day 15 |
| | 50 | 63.6 | 50 | 69.1 | 50 | 70.6 |

Percentages of V-YFP+ cells, expressing scramble vector and YFP-vector, at the start (Day 1) and end of the experiment (Day 15/Day 30). Average of three independent experiments.
expression, high PGC1α expression, and high expression of these 54 genes, suggesting a metabolic shift in these tumor samples (Fig. 4D). Interestingly, the predominant subtype of RCC within this 8% of samples was chRCC, followed by ccRCC (Fig. S8A). In the KORT database, around 32% of samples showed...
low MYBBP1A expression, high PGC1α expression, and high expression of c-MYB target genes, all of these samples being chRCCs or renal oncocytomas (Fig. S8B,C).

Finally, because we observed a shift from glycolysis to OXPHOS when we reduced MYBBP1A mRNA levels in our cellular model, we used these public databases to confirm that this metabolic shift is also observed in tumor samples. We observed a positive correlation between MYBBP1A and HK2, a key regulatory enzyme in the glycolysis pathway, in all the tested databases (Fig. 5A). Moreover, we observed a negative correlation between MYBBP1A and ADH5, DLAT and ACSS1 in the three databases. DLAT and ACSS1 are involved in the production of acetyl-CoA so that it can be used for oxidation in the TCA (Fig. 5B). Alternatively, we studied the correlation between MYBBP1A and genes of the TCA, detecting a positive correlation between MYBBP1A and ACLY and a negative correlation with 15 other genes involved in the production and oxidation of acetyl-CoA by TCA (Fig. 5C–E, Table S2). In addition, when we represented the correlation between MYBBP1A and genes of the TCA cycle on a heat map, we observed that 9% of the samples have high expression of the genes that showed negative correlation with MYBBP1A, suggesting that these samples rely on OXPHOS metabolism (Fig. 5F). Yet again, the

Fig. 5. Low MYBBP1A expression is associated with a metabolic shift from glycolysis to OXPHOS. (A) Venn diagram of glycolytic genes that correlate positively with MYBBP1A expression in the three databases analyzed. (B) Venn diagram of glycolytic genes that correlate negatively with MYBBP1A expression in the three databases analyzed. (C) Venn diagram of TCA cycle genes that correlate positively with MYBBP1A expression in the three databases analyzed. (D) Venn diagram of TCA cycle genes that correlate negatively with MYBBP1A expression in the three databases analyzed. (E) List of TCA cycle genes that correlate positively (red) and negatively (green) with MYBBP1A in each database. (F) Heat map of the TCA cycle genes that correlate positively (red bar) and negatively (green bar) with MYBBP1A in the EXPO database. Heat map was sorted by Euclidean distance.
MYBBP1A is a tumor suppressor regulating c-MYB and PGC1α

B. Felipe-Abrio et al.

The majority of these samples were chRCCs, followed by ccRCCs and pRCCs (Fig. S8D). In the KORT database, around 32% of samples showed low MYBBP1A expression and high expression of TCA genes, all of these samples being chRCCs or renal oncocytomas (Fig. S8E,F).

These correlations confirm the capability of MYBBP1A to regulate glucose metabolism through c-MYB and PGC1α in human tumors.

4. Discussion

Low glucose levels or the depletion of other nutrients cause tumors to suffer by the conflict between low energetic conditions and the high metabolic requirements. Events that allow tumor cells to grow or resist under these stringent conditions provide selective advantages over the remaining tumor cells directing clonal evolution. By performing a genetic loss-of-function screen, we found that downregulation of MYBBP1A allows cells to survive and proliferate under these conditions by switching to OXPHOS metabolism. These phenotypes are regulated through c-MYB and PGC1α. MYBBP1A is a potent tumor suppressor repressing c-MYB. Its downregulation derepresses c-MYB, which leads to transcriptional activation of PGC1α. Therefore, MYBBP1A downregulation indirectly activates PGC1α, switching the metabolism to OXPHOS and generating more energy under low glucose conditions. We believe that the combined effects elicited by MYBBP1A downregulation confer selective advantages over other tumor cells. Moreover, cells with MYBBP1A downregulation can be observed in clinically relevant renal carcinoma tumors, confirming their biological relevance.

MYBBP1A was first identified by its ability to interact specifically with c-MYB NRD through leucine zipper-like motifs (Favier and Gonda, 1994; Tanver et al., 1998). Thus, it was suggested that MYBBP1A may modulate c-MYB activity upon binding to the c-MYB NRD. Later, it was reported that MYBBP1A also binds and represses PGC1α (Fan et al., 2004). We have found that MYBBP1A reduction results in an increase in c-MYB activity, which leads to the increment of PGC1α expression. Hence, loss of MYBBP1A may simultaneously activate PGC1α by alleviating direct repression (Fan et al., 2004) and increasing the PGC1α mRNA and protein levels through c-MYB. Furthermore, p38 has been described as a PGC1α activator that blocks MYBBP1A binding to PGC1α (Fan et al., 2004). p38 activation is related to the CXCR4 pathway (Broussas et al., 2016; Zhan et al., 2016; Zuo et al., 2016), and since CXCR4 is a target gene of c-MYB (Quintana et al., 2011), activation of this transcription factor by loss of MYBBP1A (Felipe-Abrio et al., 2019) may lead to indirect activation of p38, therefore potentiating a loop leading to PGC1α activation.

PGC1α acts as a stress sensor for tumor cells activated by nutrient deficiency, oxidative damage, and chemotherapy. By participating in the maintenance of metabolic homeostasis, PGC1α promotes tumor cell survival and metastasis in restrictive microenvironments (Tan et al., 2016). Activation of PGC1α switches glycolysis to OXPHOS by decreasing glycolytic gene transcription, derepressing mitochondrial respiration, and increasing mitochondrial biogenesis as well as increasing the expression of glucose transporters, such as GLUT4 (Gannon et al., 2015). We found that loss of MYBBP1A release PGC1α activity and transcription activation through c-MYB switching tumor bioenergetics, increasing glutaminolysis and sensitivity to oxidative channel inhibition. The metabolic switch caused by MYBBP1A downregulation through both c-MYB and PGC1α activation is translated to increased proliferation in low-glucose microenvironments, providing cells a competitive advantage to survive in restrictive microenvironments and confirming the tumor suppressor activity of MYBBP1A. In addition, by participating in the maintenance of metabolic homeostasis, PGC1α promotes the survival of tumor cells and metastasis in restrictive microenvironments (Tan et al., 2016). The data from our xenograft models revealed an increment in PGC1α expression in metastasis compared to primary tumors, suggesting that PGC1α promotes metastasis as well, but the number of mice where we observed metastasis was low, so further studies will be needed to corroborate this association in mice.

On the other hand, HIF represses PGC1α and PTP1A (Du et al., 2017; LaGory et al., 2015; Soro-Arnaiz et al., 2016). Perhaps the group of renal carcinoma with low MYBBP1A better counteracts this antioxidative pressure executed by the HIF factors on PGC1α and give some ccRCC with more mitochondrial activity that possibly alters its tumor phenotype. This will also explain the competitive advantage of these low MYBBP1A tumors in a microenvironment with high oxygen and low glucose.

Both presence of c-MYB and absence of pVHL are required to detect the effect of MYBBP1A downregulation due to the exclusive relationship that we have observed between c-MYB and pVHL. Furthermore, it has been reported that all MYB family proteins, c-MYB included, may be able to interact with pVHL, namely with the isoform 3 of pVHL (Okumura et al., 2016).
2016). Indeed, B-Myb is a substrate of pVHL, the interaction being stronger between B-Myb and isoform 3 of pVHL (Okumura et al., 2016). These suggest that pVHL absence is needed in order to get a relevant expression of c-MYB, which is a key factor involved in MYBBP1A downregulation response.

Our analysis of public transcriptome databases reveals that the reduction of MYBBP1A expression occurs in a significant percentage of renal tumor samples (approx 9%). We have identified a group of tumor samples that shows low expression of MYBBP1A and high expression of PGC1α and c-MYB target genes involved in metabolic pathways. This group of tumor samples also exhibit high expression of genes involved in oxidative metabolism. This finding, together with the increased sensitivity to oxidative channel inhibition caused by MYBBP1A downregulation in vitro, suggests a possible alternative therapy for a subgroup of renal carcinoma patients. In fact, tumor cells with low MYBBP1A are more sensitive to mitochondrial respiratory channel inhibition by rotenone, suggesting some degree of dependency of these cells from the oxidative metabolism. Interestingly, the analysis of MYBBP1A low tumor samples by different subtypes of RCC points to MYBBP1A loss is more frequent in chRCCs, which could be a suitable subgroup to target oxidative pathways as an alternative therapeutic approach.

5. Conclusions

Our work reveals that MYBBP1A downregulation simultaneously activates PGC1α directly by alleviating direct repression and indirectly by increasing the PGC1α levels through c-MYB. By PGC1α activation, cellular metabolism is switched from glycolysis to OXPHOS, increasing glutaminolysis and allowing the tumor cells to adapt to harsh microenvironments, which provides a competitive advantage over other tumor cells. Interestingly, cancer cells that express c-MYB and do not express pVHL are the ones that can take advantage of MYBBP1A downregulation. In conclusion, loss of MYBBP1A is observed in a significant percentage of patients with renal cell carcinoma, who may benefit from cancer therapies that target metabolic pathways.

Acknowledgements

The authors thank Dr Ricardo Pardal, Dr Julian Aragones and Dr Sandra Muñoz Galván for critical reading of this manuscript. The AC laboratory was supported by grants from the Spanish Ministry of Science, Innovation and Universities, Plan Estatal de I+D+i 2018 cofunded by FEDER, RTI2018-097455-B-I00; the Spanish Ministry of Economy and Competitivity, Plan Estatal de I+D+i 2013-2016, ISCIII (Fis: PI15/0045) and CIBER de Cáncer (CB16/12/00275), cofunded by FEDER from Regional Development European Funds (European Union), Consejería de Ciencia e Innovación (CTS-1848), and Consejería de Salud of the Junta de Andalucía (PI-0096-2014). This work was possible thanks to the Fundacion BBVA, Fundacion AECC, and the Grant PIE13/0004 funded by the ISCIII and FEDER Funds. BF-A is funded by the Spanish Ministry of Education (FPU12/01380).

Conflict of interest

The authors declare no conflict of interest.

Author contributions

BF-A and AC designed the experiments. BF-A and EMV-S performed the experiments. AC wrote the manuscript, and AC and BF-A edited the manuscript. All authors revised the content of the manuscript.

References

Broussas M, Boute N, Akla B, Berger S, Beau-Larvor C, Champion T, Robert A, Beck A, Haeuw JF, Goetsch L et al. (2016) A new anti-CXCR1 antibody that blocks the CXCR1/SDF-1 axis and mobilizes effector cells. Mol Cancer Ther 15, 1890–1899.

Cairns RA, Harris IS and Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11, 85–95.

Carnero A and Lleonart M (2016) The hypoxic microenvironment: a determinant of cancer stem cell evolution. BioEssays 38(Suppl 1), S65–S74.

Corpe C, Sreenan S and Burant C (2001) Effects of type-2 diabetes and troglitazone on the expression patterns of small intestinal sugar transporters and PPAR-gamma in the Zucker diabetic fatty rat. Digestion 63, 116–123.

Du W, Zhang L, Brett-Morris A, Aguila B, Kerner J, Hoppel CL, Puchowicz M, Serra D, Herrero L, Rini BI et al. (2017) HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. Nat Commun 8, 1769.

Fan M, Rhee J, St-Pierre J, Handschin C, Puigserver P, Lin J, Jaeger S, Erdjument-Bromage H, Tempst P and Spiegelman BM (2004) Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK. Genes Dev 18, 278–289.

Favier D and Gonda TJ (1994) Detection of proteins that bind to the leucine zipper motif of c-Myb. Oncogene 9, 305–311.
MYBBP1A is a tumor suppressor regulating c-MYB and PGC1α

Felipe-Abrio B, Verdugo-Sivianes EM, Saez C and Carnero A (2019) Loss of MYBBP1A induces cancer stem cell activity in renal cancer. Cancers 11, E235.

Gannon NP, Schnuck JK, Mermier CM, Conn CA and Vaughan RA (2015) trans-Cinnamaldehyde stimulates mitochondrial biogenesis through PGC-1alpha and PPARbeta/delta leading to enhanced GLUT4 expression. Biochimie 119, 45–51.

Guijarro MV, Leal JF, Blanco-Aparicio C, Alonso S, Fominaya J, Leonart M, Castellvi J, Ramon y Cajal S and Carnero A (2007) MAP17 enhances the malignant behavior of tumor cells through ROS increase. Carcinogenesis 28, 2096–2104.

Kelly DP and Scarpulla RC (2004) Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev 18, 357–368.

Keough R, Woollatt E, Crawford J, Sutherland GR, Plummer S, Casey G and Gonda TJ (1999) Molecular cloning and chromosomal mapping of the human homologue of MYB binding protein (P160) 1A (MYBBP1A) to 17p13.3. Genomics 62, 483–489.

Kroemer G and Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13, 472–482.

Kumazawa T, Nishimura K, Katagiri N, Hashimoto S, Hayashi Y and Kimura K (2015) Gradual reduction in SDH mutant tumors. Mol Cell Biol 35, 10854.

LaGory EL, Wu C, Taniguchi CM, Ding CC, Chi JT, von Eyben R, Scott DA, Richardson AD and Giaccia AJ (2015) Suppression of PGC-1alpha is critical for reprogramming oxidative metabolism in renal cell carcinoma. Cell Rep 12, 116–127.

Lai Y, Qiao M, Song M, Weintraub ST and Shio Y (2011) Quantitative proteomics identifies the Myb-binding protein p160 as a novel target of the von Hippel-Lindau tumor suppressor. PLoS ONE 6, e16975.

Leal JF, Fominaya J, Cascon A, Guijarro MV, Blanco-Aparicio C, Leonart M, Castro ME, Ramon YCS, Robledo M, Beach DH et al. (2008) Celluar senescence bypass screen identifies new putative tumor suppressor genes. Oncogene 27, 1961–1970.

Lim JH, Luo C, Vazquez F and Puigserver P (2014) Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization. Can Res 74, 3535–3545.

Lorendeau D, Rinaldi G, Boon R, Spincemaille P, Metzger K, Jager C, Christen S, Dong X, Kuenen S, Voordekers K et al. (2016) Dual loss of succinate dehydrogenase (SDH) and complex I activity is necessary to recapitulate the metabolic phenotype of SDH mutant tumors. Metab Eng 43, 187–197.

Michael LF, Wu Z, Cheatham RB, Puigserver P, Adelmant G, Lehman JJ, Kelly DP and Spiegelman BM (2001) Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci USA 98, 3820–3825.

Mori S, Bernardi R, Laurent A, Resnati M, Crippa A, Gabrieli A, Keough R, Gonda TJ and Blasi F (2012) Myb-binding protein 1A (MYBBP1A) is essential for early embryonic development, controls cell cycle and mitosis, and acts as a tumor suppressor. PLoS ONE 7, e39723.

Okumura F, Uematsu K, Byrne SD, Hirano M, Joo-Oukamura A, Nishikimi A, Shuin T, Fukui Y, Nakatsukasa K and Kamura T (2016) Parallel regulation of von hippel-lindau disease by pVHL-mediated degradation of B-Myc and hypoxia-inducible factor alpha. Mol Cell Biol 36, 1803–1817.

Oriente F, Fernandez Diaz LC, Miele C, Iovino S, Mori S, Diaz VM, Troncone G, Cassese A, Formisano P, Blasi F et al. (2008) Prep1 deficiency induces protection from diabetes and increased insulin sensitivity through a p160-mediated mechanism. Mol Cell Biol 28, 5634–5645.

Puigserver P, Wu Z, Park CW, Gravess R, Wright M and Spiegelman BM (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92, 829–839.

Quintana AM, Liu F, O'Rourke JP and Ness SA (2011) Identification and regulation of c-Myb target genes in MCF-7 cells. BMC Cancer 11, 30.

Scarpulla RC (2011) Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta 1813, 1269–1278.

Soro-Arnaiz I, Li QYY, Torres-Capelli M, Melendez-Rodriguez F, Veiga S, Veyes K, Sebastian D, Elorza A, Tello D, Hernaansanz-Agustín P et al. (2016) Role of mitochondrial complex IV in age-dependent obesity. Cell Rep 16, 2991–3002.

Tan Z, Luo X, Xiao L, Tang M, Bode AM, Dong Z and Cao Y (2016) The role of PGC1alpha in cancer metabolism and its therapeutic implications. Mol Cancer Ther 15, 774–782.

Tavner FJ, Simpson R, Tashiro S, Favier D, Jenkins NA, Gilbert DJ, Copeland NG, Macmillan EM, Lutwycye J, Keough RA et al. (1998) Molecular cloning reveals that the p160 Myb-binding protein is a novel, predominantly nucleolar protein which may play a role in transactivation by Myb. Mol Cell Biol 18, 989–1002.

Ventura-Clapier R, Garnier A and Veksler V (2008) Transcriptional control of mitochondrial biogenesis:
the central role of PGC-1alpha. *Cardiovase Res* **79**, 208–217.
Warburg O (1956) On the origin of cancer cells. *Science* **123**, 309–314.
Yu SY, Kwon YI, Lee C, Apostolidis E and Kim YC (2017) Antidiabetic effect of chitosan oligosaccharide (GO2KA1) is mediated via inhibition of intestinal alpha-glucosidase and glucose transporters and PPARgamma expression. *BioFactors* **43**, 90–99.
Zhan T, Cao C, Li L, Gu N, Civin CI and Zhan X (2016) MIM regulates the trafficking of bone marrow cells via modulating surface expression of CXCR34. *Leukemia* **30**, 1327–1334.
Zuo K, Kuang D, Wang Y, Xia Y, Tong W, Wang X, Chen Y, Duan Y and Wang G (2016) SCF/c-kit transactivates CXCR35-serine 339 phosphorylation through G protein-coupled receptor kinase 6 and regulates cardiac stem cell migration. *Sci Rep* **6**, 26812.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Fig. S1. Identification of an antisense fragment against *MYBBP1A* using a genetic loss-of-function screen in the absence of glucose.
Fig. S2. Reduction of *MYBBP1A* expression in renal, pancreas and liver tumors.
Fig. S3. Downregulation of *MYBBP1A* with a second shRNA.
Fig. S4. Expression of *PGC1α* in primary tumors and metastasis.
Fig. S5. Downregulation of *MYBBP1A* induces metabolic plasticity in 786-O cell line with a second shRNA.
Fig. S6. Clonal growth of control and *MYBBP1A* downregulated cells treated with 2DG (1mM).
Fig. S7. *MYBBP1A* reduction increases tumorigenic properties in c-MYB+ and pVHL- cell lines under low glucose concentrations.
Fig. S8. Analysis of *MYBBP1A* expression and its correlation with genes involved in metabolic pathways by different subtypes of RCCs.
Table S1. Characteristics of cell lines.
Table S2. Correlation between the expression of *MYBBP1A* and genes of the TCA cycle.